Scilex Holding Company to Receive New Patent for ELYXYB Treatment
![Scilex Holding Company to Receive New Patent for ELYXYB Treatment](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Scilex Holding Company Announces New Patent for ELYXYB
Scilex today announced that the U.S. Patent and Trademark Office has allowed numerous claims from U.S. patent application no. 17/562,229 and will issue a new patent related to the treatment of acute pain to Scilex, further strengthening the Company’s intellectual property position for its acute migraine treatment drug product, ELYXYB®, a liquid, micro-encapsulation formulation of celecoxib.
About ELYXYB®
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. The U.S. oral migraine drug market size is estimated to be significant, indicating a strong demand for effective treatments.
Market Impact of ELYXYB®
As a rapid onset and ready-to-use formulation of Celecoxib, ELYXYB® provides a non-opioid therapeutic alternative to habit-forming opioids and acetaminophen, which is known for causing acute liver failure in the U.S.
Acute Pain Statistics
DelveInsight estimates there were approximately 100 million cases of acute pain in the U.S., with the total acute pain market valued at around $3 billion.
Clinical Research and Benefits
Recent studies show strong evidence supporting the use of non-steroidal anti-inflammatory drugs (NSAIDs) as first-line treatments for migraine. ELYXYB® (celecoxib oral solution) has a low incidence of gastrointestinal (GI) side effects compared to other NSAIDs, making it a viable option for patients.
Patient Responses to ELYXYB®
In clinical studies, patients using ELYXYB® experienced pain relief in as little as 15 minutes, with significant relief compared to placebo within 45 minutes in approximately 50% of patients.
Management Insights from Scilex
"We are excited about ELYXYB® since its launch. This product allows us to provide physicians with another tool to manage migraines effectively. These new patents pave the way for potential future applications in acute pain management," said Jaisim Shah, Chief Executive Officer and President of Scilex.
About Scilex Holding Company
Scilex Holding Company is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, focusing on high unmet needs and substantial market opportunities. The company’s commercial portfolio includes notable products such as ZTlido® and Gloperba®.
Company Contact Information
For more information, please contact the Company:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Frequently Asked Questions
What is the significance of the new patent for ELYXYB®?
The new patent strengthens Scilex’s intellectual property for ELYXYB®, enhancing its position in the migraine treatment market.
How does ELYXYB® work as a migraine treatment?
ELYXYB® is an oral solution that acts quickly to alleviate migraine symptoms, providing a non-opioid alternative to traditional pain relief options.
What are the potential market benefits of ELYXYB®?
The oral migraine drug market is significant, suggesting strong demand for effective treatments like ELYXYB® that address acute migraine needs.
What other products does Scilex offer?
In addition to ELYXYB®, Scilex offers ZTlido® for neuropathic pain relief and Gloperba® for gout flare prophylaxis.
Where is Scilex headquartered?
Scilex Holding Company is headquartered in Palo Alto, California.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Fnac Darty Gains CONSOB Approval for Tender Offer
- Advancements in mRNA Cancer Vaccines: A New Era of Treatment
- Aircraft Heat Exchanger Market Expected to Reach USD 3.8 Billion
- ABDS Token Launches on Uniswap: A New Era in Crypto
- PickleJar Introduces New Managed Services Innovations
- CareCloud's Preferred Stock Proposal Receives 89% Support
- Ride-Hailing and Taxi Market Growth Forecast Analysis
- Projected Growth of the Software Market to USD 2.25 Trillion
- Vow ASA Invites Shareholders to H1 2024 Results Presentation
- AEG and Onex Partners Complete Sale of ASM Global to Legends